Enarodustat for anemia in chronic kidney disease patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary clinical trials.
This study tests a daily pill that helps people with chronic kidney disease and anemia make more red blood cells, which may reduce the need for other anemia treatments. It is for patients who are not on dialysis and do not plan to start dialysis or have a kidney transplant within the next six months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 85 years old.
- Have chronic kidney disease (stage 3 to 5) and are not on dialysis.
- Your hemoglobin level is between 70 and 109 g/L (low red blood cell count), which is anemia related to kidney disease.
- You do not plan to start dialysis or have a kidney transplant in the next 24 weeks.
- Are willing to take part and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Efepoetin Alfa to treat anemia in people with chronic kidney disease who are on dialysis. The goal is to see if it can safely raise red blood cell levels and reduce the need for other anemia treatments.
This trial is for people with heart failure, chronic kidney disease, and low red blood cell counts (anemia). It examines how well the drug roxadustat helps over a long period by looking at medical records from people who have already taken it for more than a year.
This study tracks the real-world safety of desidustat in adults with anemia caused by chronic kidney disease (CKD). It’s meant to see whether the medicine is safe when used in everyday care, not just in tightly controlled settings.
This study is testing a new way to manage anemia (low red blood cells) in people on long-term dialysis. It aims to improve how doctors treat this common issue.
This trial tests enarodustat, a pill for anemia, in people with chronic kidney disease who are not on dialysis. It aims to see if it can safely raise hemoglobin levels.
This trial tests a new oral medicine (AND017) for people on dialysis who have anemia (low red blood cells). It may help reduce the need for injections of standard anemia medicines.
Hear when a new Anemia of Chronic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.